PEG-Opioid Conjugate Reduces Addiction via Controlled Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current opioid analgesics face challenges with drug addiction and abuse due to their strong euphoric effects and rapid receptor interaction, and existing solutions like opioid-antagonist combinations or polyethylene glycol conjugates either reduce analgesic efficacy or increase receptor affinity with molecular weight, limiting their clinical effectiveness.

Innovation Solution

A conjugate of polyethylene glycol (PEG) linked with 2-6 opioid units via specific linking groups, forming a stable covalent bond, which maintains superior activity with opioid receptors while reducing addictive potential, allowing for administration with smaller doses and improved pharmacokinetic profiles.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If polyethylene glycol is linked with opioids to reduce addiction potential, then addictive effect is reduced, but receptor affinity decreases as polymer molecular weight increases

Engineering Contradiction:

Improveaddiction potentialVSAvoidreceptor affinity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent divides the polyethylene glycol into multiple segments (2-6 units) linked to multiple opioid molecules, creating a conjugate structure where each PEG unit contributes to reducing addiction potential while maintaining sufficient receptor affinity through the cumulative effect of multiple opioid units

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent combines multiple opioid molecules with polyethylene glycol segments in a conjugate structure, merging the addiction-reducing properties of PEG with the receptor-activating properties of opioids to achieve both reduced addiction potential and maintained receptor affinity

Inventive Principle:

Principle #5Merging (Combining)

2Object-affected harmful factors

If opioid-antagonist combinations are used to block euphoric effects, then addiction is reduced, but analgesic efficacy decreases

Engineering Contradiction:

Improveaddiction potentialVSAvoidanalgesic efficacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent extracts the euphoric effect from the opioid action by using PEG-conjugated opioids that deliver the opioid to the brain at a constant low concentration, avoiding peak concentrations that produce euphoria and addiction, while maintaining sufficient analgesic effect through sustained release

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the concentration-time profile parameter from peak concentration (traditional delivery) to constant low concentration (PEG-conjugate delivery), transforming the pharmacokinetic profile to reduce euphoric effects and addiction potential while maintaining analgesic efficacy

Inventive Principle:

Principle #35Parameter changes

3Speed

If traditional opioid delivery methods are used, then rapid peak concentration is achieved, but addiction potential increases

Engineering Contradiction:

Improveonset speedVSAvoidaddiction potential

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent implements periodic action through the gradual release of opioid from the PEG-conjugate structure, delivering the opioid at constant low concentrations over extended periods rather than rapid peak concentrations, thereby reducing addiction potential while maintaining therapeutic effect

Inventive Principle:

Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The PEG-opioid conjugate achieves reduced addiction and abuse potential with enhanced receptor activity and prolonged analgesic effects, demonstrating improved pharmacokinetic profiles and bioavailability, particularly with double-ended PEG links, reducing peak concentrations associated with addiction.

Implementation Method 1

A conjugate of polyethylene glycol (PEG) linked with 2-6 opioid units via specific linking groups, forming a stable covalent bond

Methodology Applied

Scientific EffectCovalent bonding: Chemical Bonding

Implementation Method 2

they interact with opioid receptors (including μ, κ and δ receivers, especially μ and κ receivers) to produce analgesic effects

Methodology Applied

Scientific EffectReceptor interaction:

Implementation Method 3

which may deliver opioids to the brain at a constant low concentration, avoiding the peak concentration (which is the basis for the addiction potential)

Methodology Applied

Scientific EffectPharmacokinetic delivery:

Data Source

PatentEP3409295B1Pegylated opioid with low addictive effect

Publication Date: 2020.12.30 JENKEM TECH

AI summary

Provided in the present invention are a conjugate of polyethylene glycol and opioid as shown in general formula (I), and a pharmaceutical composition comprising the conjugate. By means of covalently bonding a plurality of opioids to a polyethylene glycol derivative, the present invention improves water solubility and pharmacokinetic property of the drug with a low addictive effect. PEG-(X-OP)m (I)